Smaller biotechs hit as Shire cuts bait on experimental drugs

Share this article:

Amicus Therapeutics announced a work-force reduction of about 20%, or 26 employees, as a part of a corporate restructuring after a commercialization deal with Shire soured.

Shire had licensed compounds in development for Fabry disease, Gaucher disease and Popme disease from the company in November 2007.

Shire also said it will terminate its collaboration with Alba Therapeutics on an experimental drug for celiac disease. Shire acquired rights to the drug, larazotide cetate, outside of the US and Japan at the end of 2007. 

As for Amicus, the biotech said reductions will occur across all levels and organizations within the company, and it is terminating relationships with contractors.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union